

# Guinea-Bissau

Population 2016

1.8 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	1.4 (0.8–2.1)	76 (44–116)
Mortality (HIV+TB only)	1.2 (0.73–1.8)	66 (40–98)
Incidence (includes HIV+TB)	6.8 (4.4–9.7)	374 (242–534)
Incidence (HIV+TB only)	2.2 (1.4–3.2)	120 (75–175)
Incidence (MDR/RR-TB)**	0.2 (0.017–0.39)	11 (0.93–21)

Estimated TB incidence by age and sex (thousands)*, 2016			
	0-14 years	> 14 years	Total
Females	0.42 (0.26–0.59)	2.2 (1.3–3)	2.6 (1.6–3.6)
Males	0.48 (0.29–0.67)	3.7 (2.3–5.2)	4.2 (2.6–5.9)
Total	0.9 (0.55–1.3)	5.9 (3.6–8.2)	6.8 (4.4–9.7)

TB case notifications, 2016	
Total cases notified	2 247
Total new and relapse	2 226
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	70%
- % pulmonary	96%
- % bacteriologically confirmed among pulmonary	83%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2016	33% (23–51)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.39 (0.21–0.6)

TB/HIV care in new and relapse TB patients, 2016		
	Number	(%)
Patients with known HIV-status who are HIV-positive	506	32%
- on antiretroviral therapy	247	49%

Drug-resistant TB care, 2016			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			67 (12–120)
Estimated % of TB cases with MDR/RR-TB	2.6% (0.1–5.1)	18% (0.1–36)	
% notified tested for rifampicin resistance			
MDR/RR-TB cases tested for resistance to second-line drugs			
Laboratory-confirmed cases		MDR/RR-TB: 37, XDR-TB:	
Patients started on treatment ****		MDR/RR-TB: 36, XDR-TB:	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2015	79%	2 147
Previously treated cases, excluding relapse, registered in 2015	100%	5
HIV-positive TB cases registered in 2015	68%	422
MDR/RR-TB cases started on second-line treatment in 2014	40%	15
XDR-TB cases started on second-line treatment in 2014		

TB preventive treatment, 2016	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	4.5% (4.1–4.9)

TB financing, 2017	
National TB budget (US\$ millions)	3.2
Funding source: 3% domestic, 71% international, 26% unfunded	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)

